Versetamide

Versetamide

SCHEMBL2109367

COCCNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)NCCOC)CC(=O)O)CC(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.50
BLM P54132 2/20 0.50
PMP22 Q01453 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
CHRM2 P08172 1/20 0.50
ADRA2A P08913 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
DRD1 P21728 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
CYP2C19 P33261 1/20 0.50
ADRA1A P35348 1/20 0.50
DRD3 P35462 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
EYA2 O00167 1/20 0.47
APP P05067 1/20 0.47
ACE P12821 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8103783 1.00 TDP1 (0.50) TDP1BLMPMP22KDM4ELMNA
Versetamide SCHEMBL15844631 0.98 TDP1 (0.48) TDP1BLMPMP22KDM4ELMNA
Versetamide SCHEMBL23202642 0.98 TDP1 (0.48) TDP1BLMPMP22KDM4ELMNA
SCHEMBL8089255 0.98 TDP1 (0.48) TDP1BLMPMP22KDM4ELMNA
Versetamide SCHEMBL17848990 0.97 TDP1 (0.47) TDP1BLMPMP22KDM4ELMNA
SCHEMBL5547592 0.91 BLM (0.50) TDP1BLMPMP22KDM4ELMNA
SCHEMBL15397125 0.90 TDP1 (0.40) TDP1BLMPMP22KDM4ELMNA
Versetamide SCHEMBL237265 0.84 KDM4E (0.43) TDP1KDM4EALOX15TSHRCYP2C19
SCHEMBL24024217 0.84 BLM (0.47) TDP1BLMPMP22KDM4ELMNA
SCHEMBL8089127 0.84 BLM (0.47) TDP1BLMPMP22KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4590277-A1 PHARMACEUTICAL COMPOSITIONS Patel, Reena (IN) 2025-07-30 EP claimed
WO-2024062443-A1 PHARMACEUTICAL COMPOSITIONS PATEL REENA (IN) 2024-03-28 WO claimed
US-11110185-B2 Combination formulation GE HEALTHCARE AS (NO) 2021-09-07 US claimed
EP-2938325-B1 DICLOFENAC COMPOSITION THEMIS MEDICARE LTD (IN) 2019-04-10 EP claimed
US-20180303960-A1 Combination Formulation GE HEALTHCARE AS (NO) 2018-10-25 US claimed
EP-3378506-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES Lutonix, Inc. (US) 2018-09-26 EP claimed
US-9289539-B2 Drug releasing coatings for medical devices LUTONIX, INC. (US) 2016-03-22 US claimed
EP-2968189-A1 METHODS FOR PREPARING INJECTABLE PROTEIN MICROPARTICLE SUSPENSIONS Ansun Biopharma, Inc. (US) 2016-01-20 EP claimed
CN-104857573-A Drug releasing coating for medical device LUTONIX INC 2015-08-26 CN claimed
US-20150209489-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES LUTONIX INC (US) 2015-07-30 US claimed
WO-2011113616-A9 A NANOPARTICLE COMPRISING A MICELLE FORMED BY AN AMPHIPHILIC BLOCK- COPOLYMER AND ENCAPSULATING A GADOLINIUM COMPLEX KING SAUD UNIVERSITY (SA) 2011-11-17 WO claimed
WO-2011119159-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES WANG LIXIAO (US) 2011-09-29 WO claimed
WO-2011113616-A1 A NANOPARTICLE COMPRISING A MICELLE FORMED BY AN AMPHIPHILIC BLOCK- COPOLYMER AND ENCAPSULATING A GADOLINIUM COMPLEX KING SAUD UNIVERSITY (SA) 2011-09-22 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20100209472-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES LUTONIX, INC. 2010-08-19 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-5508388-A REACTING DIETHYLENETRIAMINEPENTAACETIC ACID WITH ACETIC ANHYDRIDE, REACTING WITH PRIMARY OR SECONDARY AMINE TO FORM COMPLEXING AGENT, REACTING WITH PARAMAGNETIC METAL ION TO FORM COMPLEX, FILTERING, CRYSTALLIZING MALLINCKRODT MEDICAL, INC. (US) 1996-04-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11110185-B2 Combination formulation SLC10A1, SLC10A2, RXFP2 TDP1 3864/4885BLM 3032/4885PMP22 715/4885
US-20180303960-A1 Combination Formulation SLC10A1, SLC10A2, RXFP2 TDP1 3864/4885BLM 3032/4885PMP22 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.